NCT03751709 - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

March 27, 2023

Study Completion Date

November 12, 2024

Conditions

B-Cell Acute Lymphoblastic LeukaemiaALL, AdultB-ALL

Interventions

DRUG

Blinatumomab

Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.

OTHER

Haplo-Mismatched Cell Therapy (HMCT)

HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15

Trial Locations (1)

Cedars-Sinai Medical Center, Los Angeles